Alligator Bioscience (0RK9) Stock Overview
A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
0RK9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alligator Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.19 |
| 52 Week High | SEK 199.80 |
| 52 Week Low | SEK 0.19 |
| Beta | 1.38 |
| 1 Month Change | -41.81% |
| 3 Month Change | -86.90% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RK9 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.4% | 4.2% | 0.5% |
| 1Y | n/a | 38.2% | 20.0% |
Return vs Industry: Insufficient data to determine how 0RK9 performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0RK9 performed against the UK Market.
Price Volatility
| 0RK9 volatility | |
|---|---|
| 0RK9 Average Weekly Movement | 30.4% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RK9's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RK9's weekly volatility has decreased from 50% to 30% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 13 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG
Alligator Bioscience AB (publ) Fundamentals Summary
| 0RK9 fundamental statistics | |
|---|---|
| Market cap | SEK 104.50m |
| Earnings (TTM) | -SEK 77.72m |
| Revenue (TTM) | SEK 46.22m |
Is 0RK9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RK9 income statement (TTM) | |
|---|---|
| Revenue | SEK 46.22m |
| Cost of Revenue | SEK 106.63m |
| Gross Profit | -SEK 60.41m |
| Other Expenses | SEK 17.31m |
| Earnings | -SEK 77.72m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 12, 2026
| Earnings per share (EPS) | -0.15 |
| Gross Margin | -130.70% |
| Net Profit Margin | -168.15% |
| Debt/Equity Ratio | 0% |
How did 0RK9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/28 08:07 |
| End of Day Share Price | 2026/01/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alligator Bioscience AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carl Ramanius | Redeye |
| Filip Lindkvist | Redeye |